NVO - Citi Monitors Competitive Threats To Eli Lilly Says It Is Positioned To Maintain Leadership And Expand | Benzinga
Citi Research has increased the price target for Eli Lilly And Co (NYSE:LLY), reflecting increased anticipated risk-adjusted peak sales for the company’s oral small molecule GLP-1 agonist orforglipron as a mono/fixed-dose combination.
The analyst noted that the risk of drug-related liver toxicity is decreasing, with Phase 3 trials ongoing since 2023. Considering the potential peak sales of incretin drugs exceeding $85 billion for Eli Lilly, Citi says it is closely monitoring competitive threats to Eli Lilly and Novo Nordisk A/S’s (NYSE:NVO) market dominance.